Mar 21 2024University of Zurich Their study also explains why the cancer cells are resistant and how this resistance can be overcome: through concomitant pharmacotherapy or genetically improved CAR T-cells.
Mutation in blood cancer cells weakens immunotherapy defense cells An international research team led by Professors Markus Manz and Steffen Boettcher from the University of Zurich and the Department of Medical Oncology and Hematology at the University Hospital Zurich has now shown that TP53-mutant AML cells are also significantly more resistant to a new type of immunotherapy - CAR T-cell therapy - than AML cells without the mutated gene.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Research points to an immunotherapy to overcome resistant leukemiaResearchers at the University of Zurich and the University Hospital Zurich have discovered that a specific mutation in the cancer cells of an aggressive type of blood cancer can prevent novel immunotherapies such as CAR T-cell therapy from working.
Source: medical_xpress - 🏆 101. / 51 Read more »
New AI tool predicts COVID-19 vaccine uptakeFindings of a new study led by researchers at Northwestern University and the University of Cincinnati could help public health officials lead more effective vaccination campaigns that overcome hesitancy.
Source: medical_xpress - 🏆 101. / 51 Read more »
Lit from within: How tiny wireless bulbs could revolutionize clinical health careResearchers from the University of St Andrews and the University of Cologne have developed a new device platform that allows for smaller wireless light sources to be placed within the human body.
Source: medical_xpress - 🏆 101. / 51 Read more »